- Home
- SBR vs EYPT Comparison
SBR vs EYPT Comparison
Compare SBR & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- EYPT
- Stock Information
- Founded
- SBR 1982
- EYPT 1987
- Country
- SBR United States
- EYPT United States
- Employees
- SBR N/A
- EYPT N/A
- Industry
- SBR Oil & Gas Production
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- SBR Energy
- EYPT Industrials
- Exchange
- SBR Nasdaq
- EYPT Nasdaq
- Market Cap
- SBR 1.1B
- EYPT 967.4M
- IPO Year
- SBR N/A
- EYPT 2005
- Fundamental
- Price
- SBR $71.40
- EYPT $12.32
- Analyst Decision
- SBR
- EYPT Strong Buy
- Analyst Count
- SBR 0
- EYPT 5
- Target Price
- SBR N/A
- EYPT $27.40
- AVG Volume (30 Days)
- SBR 50.5K
- EYPT 1.4M
- Earning Date
- SBR 01-01-0001
- EYPT 11-05-2025
- Dividend Yield
- SBR 7.55%
- EYPT N/A
- EPS Growth
- SBR N/A
- EYPT N/A
- EPS
- SBR 5.05
- EYPT N/A
- Revenue
- SBR $77,682,730.00
- EYPT $51,898,000.00
- Revenue This Year
- SBR N/A
- EYPT N/A
- Revenue Next Year
- SBR N/A
- EYPT N/A
- P/E Ratio
- SBR $14.10
- EYPT N/A
- Revenue Growth
- SBR N/A
- EYPT 2.99
- 52 Week Low
- SBR $58.25
- EYPT $3.91
- 52 Week High
- SBR $84.39
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- SBR 50.76
- EYPT 48.55
- Support Level
- SBR $69.04
- EYPT $11.55
- Resistance Level
- SBR $72.98
- EYPT $12.47
- Average True Range (ATR)
- SBR 1.70
- EYPT 0.69
- MACD
- SBR 0.44
- EYPT -0.02
- Stochastic Oscillator
- SBR 77.04
- EYPT 47.01
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.